Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
Background Pharmacoeconomic studies examining the cost-effectiveness of adalimumab biosimilars versus methotrexate in real-life settings are limited. Objectives To assess the cost per responder from the perspective of the National Health System of adalimumab biosimilars versus methotrexate for psori...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|